Daily Endocrinology Research Analysis
Three studies advance endocrine-related care across nephrology and metabolism. A network meta-analysis of 70 RCTs in dialysis patients found sevelamer reduces all-cause mortality versus calcium-based binders, with lanthanum and sucroferric oxyhydroxide slowing coronary calcification. Real-world data show SGLT2 inhibitors protect kidney function in insulin-deficient diabetes but raise ketoacidosis risk, while a randomized crossover trial in FPLD2 demonstrates obeticholic acid markedly reduces hep
Summary
Three studies advance endocrine-related care across nephrology and metabolism. A network meta-analysis of 70 RCTs in dialysis patients found sevelamer reduces all-cause mortality versus calcium-based binders, with lanthanum and sucroferric oxyhydroxide slowing coronary calcification. Real-world data show SGLT2 inhibitors protect kidney function in insulin-deficient diabetes but raise ketoacidosis risk, while a randomized crossover trial in FPLD2 demonstrates obeticholic acid markedly reduces hepatic fat despite increasing LDL cholesterol.
Research Themes
- CKD-MBD therapy optimization and mortality outcomes
- SGLT2 inhibitors beyond type 2 diabetes: renal protection and DKA risk
- Targeted therapy for rare lipodystrophy-associated steatosis
Selected Articles
1. Efficacy and Safety of Phosphate-Lowering Agents for Adult Patients with CKD Requiring Dialysis: A Network Meta-Analysis.
Across 70 RCTs in 15,551 dialysis patients, sevelamer reduced all-cause mortality versus calcium-based binders. Lanthanum and sucroferric oxyhydroxide slowed coronary artery calcium progression, while nicotinamide and sucroferric oxyhydroxide had higher gastrointestinal adverse events.
Impact: This synthesis provides comparative effectiveness and safety signals across all major phosphate-lowering agents, including mortality differences, informing CKD-MBD treatment choices.
Clinical Implications: Prefer sevelamer over calcium-based binders when mortality reduction is prioritized; consider lanthanum or sucroferric oxyhydroxide to slow coronary calcification while balancing GI tolerability. Tenapanor may be favorable for mortality ranking but requires individual risk–benefit assessment.
Key Findings
- Sevelamer reduced all-cause mortality versus calcium-based agents (RR 0.59, 95% CI 0.37–0.94).
- Lanthanum and sucroferric oxyhydroxide slowed CACS progression vs calcium-based agents (SMD −0.26 and −0.50, respectively).
- GI events were highest with nicotinamide, followed by sucroferric oxyhydroxide.
- Calcium-based agents increased serum calcium and reduced iPTH compared with other agents; bicarbonate levels were higher with most agents except sevelamer.
Methodological Strengths
- Network meta-analysis of 70 RCTs with 15,551 participants and SUCRA ranking.
- Pre-registered protocol (PROSPERO CRD42022328388) and Cochrane risk-of-bias assessment.
Limitations
- Indirect comparisons and heterogeneity across trials and treatment durations (≥8 weeks).
- Adverse event reporting and outcomes varied between studies; potential publication bias cannot be fully excluded.
Future Directions: Head-to-head pragmatic trials and patient-level network meta-analyses are needed to validate mortality and calcification findings and to clarify GI tolerability trade-offs.
KEY POINTS: Sevelamer was associated with lower all-cause mortality compared with calcium-based agents. Sucroferric oxyhydroxide and tenapanor were estimated to rank high in lowering all-cause mortality compared with other phosphate-lowering agents. Sucroferric oxyhydroxide and lanthanum were associated with slower progression of coronary artery calcium score compared with calcium-based agents. BACKGROUND: It is necessary to update the evidence of each phosphate-lowering agent on dialysis patients. METHODS: From the CENTRAL, MEDLINE, Embase, and ClinicalTrial.gov databases, randomized controlled trials using oral phosphate-lowering agents on adult patients requiring maintenance dialysis were extracted. The treatment period was required for 8 or more weeks, and the risk of bias was assessed according to the Cochrane Collaboration method. The outcomes were all-cause mortality, cardiovascular mortality, gastrointestinal events, fracture, coronary artery calcium score (CACS), serum calcium, phosphate, intact parathyroid hormone, and bicarbonate levels. A network meta-analyses using multivariate random-effects models were performed for assessing the comparative effectiveness. The ranking of the phosphate-lowering agents was assessed using a surface under the cumulative ranking curve. RESULTS: A total of 70 randomized controlled trials involving 15,551 participants were included. Eleven phosphate-lowering agents including calcium-based agents, sevelamer, bixalomer, lanthanum, sucroferric oxyhydroxide, ferric citrate, tenapanor, magnesium, nicotinamide, aluminum, and sucralfate were assessed. Sevelamer was significantly associated with lower all-cause mortality compared with calcium-based agents (risk ratio [95% confidence interval]: 0.59 [0.37 to 0.94]), and sucroferric oxyhydroxide and tenapanor were estimated to rank high in lowering all-cause mortality on the basis of the surface under the cumulative ranking curve. The risk of gastrointestinal events was the highest with nicotinamide, followed by sucroferric oxyhydroxide. Compared with calcium-based agents, CACS was significantly lower among those on lanthanum and sucroferric oxyhydroxide (standardized mean difference [95% confidence interval]: −0.26 [−0.52 to −0.01] and −0.50 [−0.95 to−0.06], respectively). Serum calcium levels were higher, and serum intact parathyroid hormone levels were lower in patients treated with calcium-based agents. Except for sevelamer, serum bicarbonate levels for all other agents were higher compared with placebo. CONCLUSIONS: Compared with calcium-based agents, sevelamer was associated with lower all-cause mortality, and sucroferric oxyhydroxide and lanthanum were associated with slower progression of CACS. Potential benefits and harms should be considered when selecting phosphate-lowering agents (International prospective register of systematic reviews: CRD42022328388).
2. Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin-deficient phenotype: A real world analysis.
In 12,530 propensity-matched adults with insulin-deficient diabetes followed for a median 4.5 years, SGLT2 inhibitors reduced a composite kidney outcome (HR 0.79) and serum creatinine doubling (HR 0.76), and improved albuminuria. Diabetic ketoacidosis was slightly higher but infrequent.
Impact: Extends renal benefits of SGLT2 inhibitors to insulin-deficient phenotypes, informing risk–benefit discussions and candidate selection beyond type 2 diabetes.
Clinical Implications: SGLT2 inhibitors may be considered for kidney protection in insulin-deficient diabetes with careful DKA risk mitigation (education, ketone monitoring, sick-day rules). The findings support broader use while emphasizing individualized risk management.
Key Findings
- Primary composite renal outcome reduced with SGLT2i versus non-use (6.1% vs 7.5%; HR 0.79, p<0.001).
- Serum creatinine doubling reduced (HR 0.76, p<0.001); 51% transitioned to normoalbuminuria.
- DKA incidence modestly higher with SGLT2i (2.81% vs 2.19%, p=0.03), but overall low.
Methodological Strengths
- Large real-world cohort with propensity score matching and long median follow-up (1657 days).
- Consistent benefits across subgroups; multiple renal endpoints assessed.
Limitations
- Observational design with potential residual confounding and misclassification.
- DKA ascertainment and phenotype definition may vary; generalizability depends on clinical context.
Future Directions: Prospective trials in insulin-deficient populations to quantify renal benefit-risk balance and optimized DKA mitigation strategies (ketone monitoring algorithms, education).
AIM: Diabetic kidney disease (DKD) is a major complication of diabetes, including in insulin-deficient phenotypes, yet data on kidney outcomes with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in this population are limited. This study investigates the impact of SGLT2i on kidney outcomes in patients with insulin-deficient diabetes using real world data. MATERIALS AND METHODS: This retrospective cohort study utilized data from a large Health Maintenance Organization in Israel and included 12,530 propensity score-matched adults with insulin-deficient diabetes. Patients were categorized into SGLT2i users and non-users and followed for a median of 1657 days. The primary outcome was a composite of ≥50% decline in eGFR to <60 mL/min/1.73 m RESULTS: SGLT2i use was associated with a reduced incidence of the primary outcome (6.1% vs. 7.5%; HR 0.79, p < 0.001). Secondary analyses revealed significant reductions in serum creatinine doubling (HR 0.76, p < 0.001) and improvements in albuminuria, with 51% of SGLT2i users transitioning to normoalbuminuria. Benefits were consistent across subgroups. Although diabetic ketoacidosis (DKA) incidence was higher among SGLT2i users (2.81% vs. 2.19%, p = 0.03), the overall frequency was low. CONCLUSIONS: SGLT2i demonstrated substantial kidney protection in insulin-deficient patients, extending benefits beyond type 2 diabetes. These findings highlight SGLT2i as a potential therapeutic option for mitigating DKD in high-risk populations.
3. Efficacy and Safety of Obeticholic Acid for Treating Hepatic Steatosis in Patients With Familial Partial Lipodystrophy.
In a double-blind crossover RCT of 10 women with FPLD2, obeticholic acid reduced liver fat by 39.6% versus placebo without changes in triglycerides or transaminases, but increased LDL cholesterol by 24%. Pruritus occurred more often with OCA.
Impact: Demonstrates a targeted pharmacologic option to reduce hepatic steatosis in a rare endocrine-metabolic disorder, generating evidence for FXR agonism in lipodystrophy.
Clinical Implications: For FPLD2 with hepatic steatosis, OCA may reduce liver fat; clinicians should monitor LDL cholesterol and pruritus. Results support consideration in clinical trials or specialized care settings.
Key Findings
- OCA reduced MRI-PDFF liver fat by 39.6% versus placebo (median 6.4% vs 10.6%; interaction p=0.03).
- No significant changes in serum triglycerides or transaminases with OCA vs placebo.
- LDL cholesterol increased by 24% with OCA (mean 129 vs 104 mg/dL; p=0.0016); pruritus more frequent with OCA.
Methodological Strengths
- Randomized, double-blind, placebo-controlled crossover design in a genetically defined FPLD2 cohort.
- Quantitative liver fat measurement by MRI-PDFF.
Limitations
- Small single-center study (n=10), limited to women with FPLD2; short treatment periods.
- LDL increase warrants careful cardiovascular risk assessment.
Future Directions: Larger multicenter trials to confirm efficacy, define lipid management strategies with FXR agonists, and assess histologic and clinical outcomes.
CONTEXT: Patients with familial partial lipodystrophy (FPLD) have increased risk of hepatic steatosis and its complications, for which there is no approved therapy. OBJECTIVE: This work aimed to investigate the efficacy and safety of obeticholic acid (OCA), a farnesoid X receptor agonist, for reducing hepatic steatosis in patients with FPLD. METHODS: A randomized, double-blind, placebo-controlled, crossover trial was conducted at an academic referral center. Ten women (age 19-60 years) with the Dunnigan variety of FPLD (FPLD2), harboring pathogenic heterozygous variants in the lamin A/C gene and hepatic steatosis (liver fat >5.6% by proton-density fat fraction mapping by magnetic resonance imaging), were included. Intervention included OCA 25 mg daily vs matched placebo for 4 months each with a 4-month washout period in between. The primary end point variable was liver fat. Secondary end point variables were serum triglycerides (TGs) and transaminase levels. RESULTS: All patients completed the trial. OCA therapy caused significant (39.6%) reduction in liver fat as compared to placebo (median liver fat [minimum-maximum]; 6.4% [2.4%-18.0%] vs 10.6% [3.4%-29.3%], respectively; P value for treatment × month interaction = .03). There were no significant differences in serum TGs or transaminase levels during OCA and placebo therapy. Overall, OCA was well tolerated except for itching in 4 patients compared to 2 on placebo. OCA, as compared to placebo, caused 24% increase in serum low-density lipoprotein cholesterol (mean 129 mg/dL vs 104 mg/dL, respectively; P = .0016). CONCLUSION: OCA is safe and effective in lowering hepatic TG levels in patients with FPLD2.